Exploring Further Avenues for Menin Inhibition in Acute Myeloid Leukemia

Naval G. Daver, MD, and Eytan M. Stein, MD, discuss how menin inhibitors may transform the treatment paradigm in NPM1-mutant and NUP98 fusion AML.

Eytan M. Stein, MD, discusses the emerging role of menin inhibitors such as revumenib in combination treatment strategies for AML.

Naval Daver, MD, discusses the evolving role of menin inhibition in acute myeloid leukemia and emerging data with revumenib.

Naval G. Daver, MD, highlights the efficacy of revumenib for the treatment of patients with NPM1-mutant relapsed/refractory acute myeloid leukemia.